GALAPAGOS NV/S (NASDAQ:GLPG) Upgraded by Zacks Investment Research to “Buy”
Zacks Investment Research upgraded shares of GALAPAGOS NV/S (NASDAQ:GLPG) from a hold rating to a buy rating in a research report report published on Wednesday, Zacks.com reports. Zacks Investment Research currently has $152.00 price target on the biotechnology company’s stock.
According to Zacks, “Galapagos NV is a biotechnology company. The Company’s operating segment consists of Research and Development and Services. Research and Development segment is engaged in the discovery and development of small molecules. Services segment offers drug discovery products and services. Its products include GLPG0634 for the treatment of rheumatoid arthritis and other inflammatory diseases, GLPG1205/GLPG1690 for treating inflammatory bowel disease, GSK2586184 for the treatment of chronic immuno-inflammatory diseases and GLPG0974, to prevent free fatty acid-induced activation and migration of neutrophils which are in different clinical trial. Galapagos NV is headquartered in Mechelen, Belgium. “
A number of other equities research analysts have also recently commented on the stock. ValuEngine upgraded shares of XPO Logistics from a strong sell rating to a sell rating in a research note on Thursday, April 4th. Cantor Fitzgerald restated a buy rating and set a $25.00 target price on shares of Menlo Therapeutics in a research note on Thursday, May 2nd. Morgan Stanley raised their target price on shares of Thomson Reuters from $66.00 to $67.00 and gave the stock an overweight rating in a research note on Monday, April 29th. HC Wainwright set a $10.00 target price on shares of Jaguar Health and gave the stock a buy rating in a research note on Tuesday, July 2nd. Finally, BidaskClub cut shares of Amyris from a hold rating to a sell rating in a research note on Thursday, June 27th. One equities research analyst has rated the stock with a hold rating, twelve have given a buy rating and two have issued a strong buy rating to the company. The company currently has an average rating of Buy and an average target price of $134.90.
GALAPAGOS NV/S (NASDAQ:GLPG) last released its earnings results on Friday, April 26th. The biotechnology company reported ($1.01) EPS for the quarter, topping analysts’ consensus estimates of ($1.19) by $0.18. GALAPAGOS NV/S had a negative net margin of 13.24% and a negative return on equity of 3.60%. The company had revenue of $46.47 million for the quarter, compared to analysts’ expectations of $44.92 million. As a group, research analysts predict that GALAPAGOS NV/S will post -4.61 earnings per share for the current year.
Several institutional investors have recently added to or reduced their stakes in GLPG. Bank of New York Mellon Corp raised its position in shares of GALAPAGOS NV/S by 530.8% during the fourth quarter. Bank of New York Mellon Corp now owns 249,137 shares of the biotechnology company’s stock valued at $22,857,000 after buying an additional 209,642 shares during the last quarter. FMR LLC raised its position in shares of GALAPAGOS NV/S by 35.3% during the first quarter. FMR LLC now owns 502,193 shares of the biotechnology company’s stock valued at $59,148,000 after buying an additional 131,119 shares during the last quarter. Norges Bank bought a new stake in shares of GALAPAGOS NV/S during the fourth quarter valued at approximately $6,422,000. OLD Mission Capital LLC raised its position in shares of GALAPAGOS NV/S by 103.2% during the fourth quarter. OLD Mission Capital LLC now owns 34,209 shares of the biotechnology company’s stock valued at $3,138,000 after buying an additional 17,378 shares during the last quarter. Finally, D. E. Shaw & Co. Inc. raised its position in shares of GALAPAGOS NV/S by 354.6% during the fourth quarter. D. E. Shaw & Co. Inc. now owns 19,093 shares of the biotechnology company’s stock valued at $1,752,000 after buying an additional 14,893 shares during the last quarter. Hedge funds and other institutional investors own 16.33% of the company’s stock.
About GALAPAGOS NV/S
Galapagos NV, a clinical-stage biotechnology company, discovers, develops, and commercializes novel medicines. Its clinical stage programs include filgotinib, which is in Phase III clinical trials for the treatment of rheumatoid arthritis and Crohn's disease, Phase 2/3 trials for ulcerative colitis, and Phase II trials for multiple additional indications; GLPG1690, an autotaxin inhibitor, which is in Phase III clinical trial for the treatment of idiopathic pulmonary fibrosis; GLPG1972 that completed Phase 1b clinical trial for the treatment of osteoarthritis; and MOR106, which is in Phase II trials for atopic dermatitis patients.
Further Reading: Relative Strength Index
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for GALAPAGOS NV/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GALAPAGOS NV/S and related companies with MarketBeat.com's FREE daily email newsletter.